A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast cancers

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 5, 2012, Pages 1363-1368

  Lin, Che ^a,b   Chen, Dar Ren ^a   Chang, King Jen ^c   Chang, Tsai Wang ^d   Wang, Hwei Chung ^e  

^a CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Breast cancer; Cisplatin; Docetaxel; HER2; Trastuzumab

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ADJUVANT THERAPY; ADULT; ALOPECIA; ANEMIA; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; GENE OVEREXPRESSION; HEART DEATH; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPOTENSION; LEUKOPENIA; LOADING DRUG DOSE; LUNG METASTASIS; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; OPEN STUDY; PARTIAL MASTECTOMY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TAIWAN; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME; BREAST TUMOR; CLINICAL TRIAL; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; TAIWAN; TAXOIDS; TREATMENT OUTCOME;

EID: 84862270671     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1841-y     Document Type: Article

References (25)

1. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triplenegative breast cancer. J Clin Oncol 26:1275-1281
2. Ezzat AA, Ibrahim EM, Ajarim DS, Rahal MM, Raja MA, Tulbah AM, Al-Malik OA, Al-Shabanah M, Sorbris R (2004) Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients. Br J Cancer 90:968-974 (Pubitemid 38495813)
3. Pegram MD, Pienkowski T, Northfelt DW, Eiermann W, Patel R, Fumoleau P, Quan E, Crown J, Toppmeyer D, Smylie M, Riva A, Blitz S, Press MF, Reese D, Lindsay MA, Slamon DJ (2004) Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Natl Cancer Inst 96:759-769 (Pubitemid 38771821)
4. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-3685
5. Buzdar AU (2007) Adjuvant chemotherapy for high-risk operable breast cancer. J Clin Oncol 25:1642-1644 (Pubitemid 46797940)
6. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, Albain K, McCullough C, Fuchs L, Slamon D (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786-2792 (Pubitemid 46630577)
7. Coudert BP, Arnould L, Moreau L, Chollet P, Weber B, Vanlemmens L, Molucon C, Tubiana N, Causeret S, Misset JL, Feutray S, Mery-Mignard D, Garnier J, Fumoleau P (2006) Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 17:409-414 (Pubitemid 43329576)
8. Yaal-Hahoshen N, Safra T (2006) Herceptin (trastuzumab): adjuvant and neoadjuvant trials. Isr Med Assoc J 8:416-421 (Pubitemid 43986056)
9. Chang JC (2007) HER2 inhibition: from discovery to clinical practice. Clin Cancer Res 13:1-3 (Pubitemid 46121845)
10. Untch M, von Minckwitz G (2009) Recent advances in systemic therapy: advances in neoadjuvant (primary) systemic therapy with cytotoxic agents. Breast Cancer Res 11:203
11. Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Kuhn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, von Minckwitz G (2010) Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 28:2024-2031
12. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, Zambetti M, Vazquez F, Byakhow M, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Baronio R, Feyereislova A, Barton C, Valagussa P, Baselga J (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377-384
13. Gonzalez RJ, Buzdar AU, Fraser Symmans W, Yen TW, Broglio KR, Lucci A, Esteva FJ, Yin G, Kuerer HM (2007) Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). Breast J 13:72-75 (Pubitemid 46046497)
14. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792 (Pubitemid 32222155)
15. Lin C, Chien SY, Chen LS, Kuo SJ, Chang TW, Chen DR (2009) Triple negative breast carcinoma is a prognostic factor in Taiwanese women. BMC Cancer 9:192
16. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO (2008) Basal-like breast cancer defined by Wve biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368-1376 (Pubitemid 351413917)
17. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373-2378
18. Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26:2568-2581
19. Kurebayashi J, Moriya T, Ishida T, Hirakawa H, Kurosumi M, Akiyama F, Kinoshita T, Takei H, Takahashi K, Ikeda M, Nakashima K (2007) The prevalence of intrinsic subtypes and prognosis in breast cancer patients of diVerent races. Breast 16(Suppl 2):S72-S77
20. Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, Mone M, Hansen H, Buys SS, Rasmussen K, Orrico AR, Dreher D, Walters R, Parker J, Hu Z, He X, Palazzo JP, Olopade OI, Szabo A, Perou CM, Bernard PS (2006) Classification and risk stratification of invasive breast carcinomas using a realtime quantitative RT-PCR assay. Breast Cancer Res 8:R23
21. Adams AL, Eltoum I, Krontiras H, Wang W, Chhieng DC (2008) The eVect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma. Breast J 14:141-146 (Pubitemid 351341835)
22. Madarnas Y, Trudeau M, Franek JA, McCready D, Pritchard KI, Messersmith H (2008) Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review. Cancer Treat Rev 34:539-557
23. D'Alfonso T, Liu YF, Monni S, Rosen PP, Shin SJ (2010) Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed. Am J Surg Pathol 34:575-581
24. Cameron DA (2011) Chemotherapy, trastuzumab, and pathological complete response: when shall we three meet again? J Clin Oncol 29:3344-3346
25. Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, Camara O, Muller V, du Bois A, Kuhn T, Stickeler E, Harbeck N, Hoss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29:3351-3357